

Streamlining Staging of Colorectal cancer with Whole Body MRI

Submission date 24/07/2012	Recruitment status No longer recruiting	☒ Prospectively registered ☐ Protocol
Registration date 25/07/2012	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 20/12/2019	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol

<http://www.cancerresearchuk.org/cancer-help/trials/a-study-looking-mri-scan-diagnose-bowel-cancer-streamline-c>

Contact information

Type(s)

Scientific

Contact name

Prof Stuart Taylor

Contact details

University College London
University College London Hospitals
Specialist X Ray Department
235 Euston Road
London
United Kingdom
NW1 2BU

-
stuart.taylor1@nhs.net

Additional identifiers

Study information

Scientific Title

Comprehensive staging of newly diagnosed colorectal cancer: prospective multi-centre comparison of whole body Magnetic Resonance Imaging with standard diagnostic imaging pathways

Acronym

Streamline C

Study objectives

To evaluate whether early whole body magnetic resonance Imaging (WB-MRI) increases per patient sensitivity for metastasis in colorectal cancer compared to standard NICE-approved diagnostic pathways.

More details can be found at <http://www.hta.ac.uk/project/2804.asp>

Ethics approval required

Old ethics approval format

Ethics approval(s)

Camden and Islington Research Ethics Committee, 20 August 2012, ref: 12/LO/1176

Primary study design

Interventional

Study design

Multicentre comparison

Study type(s)

Screening

Health condition(s) or problem(s) studied

Colorectal cancer

Interventions

5. There are no treatment arms, every patient will receive a whole body MRI as part of the trial which takes about an hour. Aside from attending for the WB-MRI scan, patients shouldn't have to attend for any extra visits. All patients will be asked to complete quality of life forms (EQ-5D) at 0, 3, 6 and 9 months post staging. As part of the health economics portion of the trial, all patients will also be asked to complete patient diaries which will collect information about visits to the GP and hospital and about other medical tests and treatment for a year post staging. As part of the health psychology portion of the trial, 25 patients will take part in an interview (30 minutes) and 75 patients will be given questionnaires complete about their experience of staging at 0, 1, 3, 6, 9, and 12 months post staging. Follow-up CRFs will be completed for a year post-staging but there are no trial specific visits, this data is collected for the health economic portion of trial.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Per patient sensitivity for metastasis detection by whole body MRI (WB-MRI) compared to standard staging pathways in newly diagnosed colorectal cancer

Key secondary outcome(s)

1. The time and test number taken to reach, and the nature of, the first major treatment decision based on WB-MRI in comparison to standard staging pathways.
2. Diagnostic accuracy of WB-MRI and conventional staging pathways for local tumour staging and detection of metastasis in comparison to an expert derived consensus reference standard.
3. Lifetime incremental cost and cost-effectiveness of staging using WB-MRI compared to standard diagnostic pathways.
4. Patient experience of staging using WB-MRI in comparison to standard diagnostic pathways and priorities placed by patients on differing attributes related to competing staging pathways.
5. Inter-observer variability in WB-MRI analysis and affect of diagnostic confidence on staging accuracy.
6. Diagnostic accuracy of limited T1 and diffusion weighted sequences compared to full multi-sequence WB-MRI protocols.

Completion date

01/01/2019

Eligibility**Key inclusion criteria**

1. Adult patients (18 or over) with histologically proven or suspected colorectal cancer referred for staging.
2. Suspicion of colorectal cancer defined as: Presence of a mass highly suspicious for colorectal cancer on endoscopy, barium enema, CT colonography or other imaging which triggers staging investigations.
3. Patient must have given written informed consent and be willing to comply with the protocol intervention and follow up.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Total final enrolment

370

Key exclusion criteria

1. Any psychiatric or other disorder likely to impact on informed consent
2. Evidence of severe or uncontrolled systemic disease which make it undesirable for the patient to participate in the trial

3. Pregnancy
4. Contraindications to MRI (e.g. cardiac pacemaker, severe claustrophobia, inability to lie flat)
5. Polyp cancer (because metastatic disease in these patients is vanishingly rare)

Date of first enrolment

01/10/2012

Date of final enrolment

01/04/2017

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

University College London

London

United Kingdom

NW1 2BU

Sponsor information

Organisation

University College London (UK)

ROR

<https://ror.org/02jx3x895>

Funder(s)

Funder type

Not defined

Funder Name

NIHR Health Technology Assessment Programme - HTA (UK) ref: 10/68/01

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	result	01/07/2019	14/05/2019	Yes	No
Results article	comparative results against ISRCTN50436483	01/12/2019	20/12/2019	Yes	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes